Proposing Specific Neuronal Epithelial-to-Mesenchymal Transition Genes as an Ancillary Tool for Differential Diagnosis among Pulmonary Neuroendocrine Neoplasms.
diagnosis
epithelial-to-mesenchymal transition
metastasis
morphology
pulmonary neuroendocrine neoplasms
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
07 12 2022
07 12 2022
Historique:
received:
28
09
2022
revised:
25
11
2022
accepted:
29
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Pulmonary neuroendocrine neoplasms (PNENs) are currently classified into four major histotypes, including typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell lung carcinoma (SCLC). This classification was designed to be applied to surgical specimens mostly anchored in morphological parameters, resulting in considerable overlapping among PNENs, which may result in important challenges for clinicians' decisions in the case of small biopsies. Since PNENs originate from the neuroectodermic cells, epithelial-to-mesenchymal transition (EMT) gene expression shows promise as biomarkers involved in the genotypic transformation of neuroectodermic cells, including mutation burden with the involvement of chromatin remodeling genes, apoptosis, and mitosis rate, leading to modification in final cellular phenotype. In this situation, additional markers also applicable to biopsy specimens, which correlate PNENs subtypes with systemic treatment response, are much needed, and current potential candidates are neurogenic EMT genes. This study investigated EMT genes expression and its association with PNENs histotypes in tumor tissues from 24 patients with PNENs. PCR Array System for 84 EMT-related genes selected 15 differentially expressed genes among the PNENs, allowing to discriminate TC from AC, LCNEC from AC, and SCLC from AC. Functional enrichment analysis of the EMT genes differentially expressed among PNENs subtypes showed that they are involved in cellular proliferation, extracellular matrix degradation, regulation of cell apoptosis, oncogenesis, and tumor cell invasion. Interestingly, four EMT genes (
Identifiants
pubmed: 36553576
pii: genes13122309
doi: 10.3390/genes13122309
pmc: PMC9777553
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Oncol. 2011 May;38(5):1197-217
pubmed: 21318221
J Pathol. 2017 Mar;241(4):488-500
pubmed: 27873319
Hum Pathol. 1998 Mar;29(3):272-9
pubmed: 9496831
BMC Cancer. 2018 May 4;18(1):530
pubmed: 29728073
Tumour Biol. 2014 Oct;35(10):9725-33
pubmed: 24972966
Nat Commun. 2018 Mar 13;9(1):1048
pubmed: 29535388
JAMA Oncol. 2017 Oct 01;3(10):1335-1342
pubmed: 28448665
J Clin Pathol. 2001 Jul;54(7):498-9
pubmed: 11429418
Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907
pubmed: 31886121
Ann Oncol. 2015 Aug;26(8):1604-20
pubmed: 25646366
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Breast Cancer Res. 2012 Jan 19;14(1):202
pubmed: 22264257
Transl Lung Cancer Res. 2020 Oct;9(5):2233-2244
pubmed: 33209646
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Bioengineered. 2022 Apr;13(4):9049-9062
pubmed: 35400271
Am J Surg Pathol. 2002 Sep;26(9):1184-97
pubmed: 12218575
PLoS One. 2014 Jun 24;9(6):e100249
pubmed: 24959847
J Thorac Oncol. 2018 Jun;13(6):752-766
pubmed: 29454048
Int J Oncol. 2015 Apr;46(4):1461-72
pubmed: 25652255
Am J Surg Pathol. 2014 Oct;38(10):1429-36
pubmed: 25046341
Transl Lung Cancer Res. 2017 Oct;6(5):513-529
pubmed: 29114468
Mol Pharmacol. 2020 Feb;97(2):72-89
pubmed: 31787618
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562726
Mol Biol Cell. 2008 Nov;19(11):4738-49
pubmed: 18716062
Cancer Res. 2020 Dec 1;80(23):5216-5230
pubmed: 33023950
J Thorac Oncol. 2017 Feb;12(2):334-346
pubmed: 27998793
Virchows Arch. 2017 Feb;470(2):153-164
pubmed: 28054150
Sci Rep. 2019 Jan 22;9(1):270
pubmed: 30670749
Pancreas. 2010 Aug;39(6):713-34
pubmed: 20664471
Nucleic Acids Res. 2019 Jan 8;47(D1):D948-D954
pubmed: 30247620
Nat Rev Cancer. 2019 May;19(5):289-297
pubmed: 30926931
J Invest Dermatol. 2009 Feb;129(2):491-5
pubmed: 18685621
BMC Cancer. 2014 Nov 20;14:855
pubmed: 25413006
Histopathology. 2010 Feb;56(3):356-63
pubmed: 20459535
Genome Biol. 2006;7(6):224
pubmed: 16938900
Virchows Arch. 2012 Mar;460(3):299-308
pubmed: 22293945
Front Oncol. 2014 Jun 18;4:153
pubmed: 24995158
Radiol Clin North Am. 2011 May;49(3):529-48, vii
pubmed: 21569909
Clin Cancer Res. 2007 May 15;13(10):2849-54
pubmed: 17504982
Cytoskeleton (Hoboken). 2010 Aug;67(8):535-44
pubmed: 20607860
J Clin Med. 2016 Jan 19;5(1):
pubmed: 26797644
Nucleic Acids Res. 2019 Jan 8;47(D1):D607-D613
pubmed: 30476243
Histopathology. 2021 Apr;78(5):699-709
pubmed: 33025627
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Visc Med. 2017 Oct;33(5):324-330
pubmed: 29177160
Am J Pathol. 2006 Oct;169(4):1390-401
pubmed: 17003494
Lung Cancer. 2020 Jul;145:85-94
pubmed: 32417679
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Front Oncol. 2021 Aug 30;11:645623
pubmed: 34527572
Cancers (Basel). 2019 Oct 08;11(10):
pubmed: 31597385
Anticancer Res. 2019 Apr;39(4):1821-1827
pubmed: 30952722
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7624-9
pubmed: 19380745
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Biosci Rep. 2022 Jan 28;42(1):
pubmed: 34708244
J Thorac Oncol. 2022 Mar;17(3):362-387
pubmed: 34808341
Biochem Biophys Res Commun. 2018 Feb 5;496(2):381-386
pubmed: 29326042
Clin Cancer Res. 2020 Feb 15;26(4):892-901
pubmed: 31694833
Am J Clin Pathol. 2001 Oct;116(4):466-72
pubmed: 11601129